Groups Similar Look up By Text Browse About



Similar articles
Article Id Title Prob Score Similar Compare
220739 THEVERGE 2021-11-19:
FDA clears Pfizer and Moderna COVID-19 boosters for all US adults
1.000 Find similar Compare side-by-side
220648 ARSTECHNICA 2021-11-19:
FDA authorizes Pfizer and Moderna COVID boosters for all adults
0.989 0.629 Find similar Compare side-by-side
220921 ARSTECHNICA 2021-11-19:
Adults nationwide eligible for boosters this weekend as CDC gives sign-off
0.864 0.622 Find similar Compare side-by-side
220683 ARSTECHNICA 2021-11-17:
Boosters for all is critical, not a luxury, Fauci says as FDA decision nears
0.092 0.594 Find similar Compare side-by-side
220902 ARSTECHNICA 2021-11-22:
COVID surge underway with daily cases already above 93K ahead of holiday
0.004 0.455 Find similar Compare side-by-side
220488 ARSTECHNICA 2021-11-16:
Doctors are fighting back against fringe doctors pushing COVID misinformation
0.381 Find similar Compare side-by-side
220714 ZDNET 2021-11-19:
South Australia launches two digital tools for assessing travellers as part of opening border
0.314 Find similar Compare side-by-side
220861 VENTUREBEAT 2021-11-20:
The one thing we’re NOT doing to mitigate the spread of COVID-19
0.300 Find similar Compare side-by-side
220772 TECHREPUBLIC 2021-11-18:
Office occupancy hits 25% in the US with NYC and Boston offices filling up the fastest
0.281 Find similar Compare side-by-side
220383 VENTUREBEAT 2021-11-16:
No-code customer journey company EasySend gets $55.5M
0.233 Find similar Compare side-by-side
220461 ARSTECHNICA 2021-11-16:
California says Amazon must stop hiding COVID case counts from workers
0.232 Find similar Compare side-by-side
220376 TECHREPUBLIC 2021-11-17:
How to protect your organization from ransomware attacks during the holiday season
0.228 Find similar Compare side-by-side
220991 VENTUREBEAT 2021-11-19:
Report: Only half of companies employ a CISO
0.224 Find similar Compare side-by-side
220315 VENTUREBEAT 2021-11-17:
Groq accelerates COVID drug discovery at Argonne National Laboratory
0.221 Find similar Compare side-by-side
220327 THEVERGE 2021-11-16:
Uber reintroduces shared rides with a new name
0.216 Find similar Compare side-by-side
220646 VENTUREBEAT 2021-11-19:
Biopharma Industry Leaders Ian Read and Clive Meanwell Join Saama Board of Directors
0.211 Find similar Compare side-by-side
220795 VENTUREBEAT 2021-11-19:
Report: 56% of workers admit they’ve accidentally deleted cloud data
0.205 Find similar Compare side-by-side
220725 VENTUREBEAT 2021-11-18:
Report: Nearly half of online shoppers will cut ties with a retailer if personal info is compromised
0.205 Find similar Compare side-by-side
220894 VENTUREBEAT 2021-11-22:
Teal Bio, Inc. Announces Oversubscribed Series A Funding Round
0.200 Find similar Compare side-by-side
220687 THEVERGE 2021-11-18:
Several states are investigating how Instagram keeps kids on the platform
0.199 Find similar Compare side-by-side
220693 ARSTECHNICA 2021-11-18:
Theranos gave woman false-positive HIV result, then ghosted her
0.198 Find similar Compare side-by-side
220665 THEVERGE 2021-11-18:
US government seizes $56 million in crypto from BitConnect’s ‘number one promoter’
0.197 Find similar Compare side-by-side
220361 VENTUREBEAT 2021-11-16:
Report: 69% of businesses say cloud technologies helped their pandemic recovery
0.197 Find similar Compare side-by-side
220790 VENTUREBEAT 2021-11-18:
Report: 98% of IT leaders concerned about security challenges due to hybrid workforce
0.195 Find similar Compare side-by-side
220358 ZDNET 2021-11-17:
Remote work: Developers aren't planning to go back to the office
0.195 Find similar Compare side-by-side

1

ID: 220739

URL: https://www.theverge.com/2021/11/19/22786103/fda-pfizer-moderna-booster-eligibility-adults

Date: 2021-11-19

FDA clears Pfizer and Moderna COVID-19 boosters for all US adults

The Food and Drug Administration opened booster shots for the Pfizer / BioNTech and Moderna COVID-19 vaccine to all adults today, the companies announced, expanding eligibility outside of the initial, vulnerable groups they were cleared for earlier this fall. Although the COVID-19 vaccines available in the United States are still highly effective protection against severe cases of the disease, hospitalization, and death, protection against any infection or symptoms appears to be weakening. A third, booster shot of the vaccines could restore that protection: Pfizer showed in a clinical trial that the shot was around 95 percent effective compared with people who only had two doses, essentially restoring the same efficacy seen in the initial clinical trials. Analysis out of Israel and the United Kingdom, which have been using booster doses for longer than the US, also show that a third shot significantly blunts infection rates. Theyre available to anyone over 40 in the United Kingdom and anyone over 12 in Israel. Until now, booster shots of the Pfizer / BioNTech and Moderna COVID-19 vaccines were officially available to people 65 years of age and older, those who are at high risk of severe disease, healthcare workers, and other people at high risk of exposure to COVID-19 at work. However, in response to recent upticks in infection rates, some states have moved ahead and started offering third doses to everyone. (Everyone who got the one-shot Johnson & Johnson COVID-19 vaccine is already eligible for a second dose). Just over 16 percent of people in the United States who had an initial vaccine series have already received a booster shot.